Ali Khan

Dr. Ali Khan

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2021 in Molecular Aspects of Medicine
Verified
Journal Article
Closed access
DMDevashish Mehta
Devashish Mehta
VSVarsha Saini
Varsha Saini
BABharti Aggarwal
Bharti Aggarwal
AKAli Khan
Ali Khan
ABAvinash Bajaj
Avinash Bajaj

20 January 2023 in International Journal of Cancer
Verified
Journal Article
Closed access
AKAnimesh Kar
Animesh Kar
NMNihal Medatwal
Nihal Medatwal
KRKajal Rajput
Kajal Rajput
SMSusmita Mandal
Susmita Mandal
TPTrishna Pani
Trishna Pani
UDUjjaini Dasgupta
Ujjaini Dasgupta

1 May 2024 in Nanoscale
Verified
Journal Article
Open access
PDF file
PYPoonam Yadav
Poonam Yadav
KRKajal Rana
Kajal Rana
RCRuchira Chakraborty
Ruchira Chakraborty
AKAli Khan
Ali Khan
DMDevashish Mehta
Devashish Mehta
ABAvinash Bajaj
Avinash Bajaj
Tumour cells secrete various proangiogenic factors like VEGF, PDGF, and EGF that result in the formation of highly vascularized tumours with an immunosuppressive tumour microenvironment.

13 March 2024 in Journal of Controlled Release
Verified
Journal Article
Closed access
PYPoonam Yadav
Poonam Yadav
KRKajal Rana
Kajal Rana
VNViviani Nardini
Viviani Nardini
AKAli Khan
Ali Khan
TPTrishna Pani
Trishna Pani
ABAvinash Bajaj
Avinash Bajaj

11 September 2025 in PLOS Biology
Verified
Journal Article
Open access
PDF file
MAMohammad Nafees Ansari
Mohammad Nafees Ansari
SJSomesh K. Jha
Somesh K. Jha
AKAli Khan
Ali Khan
KRKajal Rajput
Kajal Rajput
NPNishant Pandey
Nishant Pandey
UDUjjaini Dasgupta
Ujjaini Dasgupta
Sphingolipid and ganglioside metabolic pathways are crucial components of cell signaling, having established roles in cancer cell proliferation, invasion, and migration. However, regulatory mechanisms controlling sphingolipid and ganglioside biosynthesis in mammalian cells are less known. Here, we show that RICTOR, the regulatory subunit of mTORC2, regulates the synthesis of sphingolipids and gangliosides in human luminal breast cancer-specific MCF-7 and BT-474 cells through transcriptional and epigenetic mechanisms. We observe that RICTOR regulates glucosylceramide levels by modulating the expression of UDP-Glucose Ceramide Glucosyl transferase (UGCG). We identify Zinc Finger protein X-linked (ZFX) as a RICTOR-responsive transcription factor whose recruitment to the UGCG promoter is regulated by DNA methyltransferase 1 and histone demethylase (KDM5A), which are known AKT substrates. We further demonstrate that RICTOR regulates the synthesis of GD3 gangliosides through ZFX and UGCG, and triggers the activation of the EGFR signaling pathway, thereby promoting tumor growth. In line with our findings in human cell culture and mouse models, we observe an elevated expression of RICTOR, ZFX, and UGCG in Indian luminal breast cancer tissues and in TCGA and METABRIC datasets. Together, we establish a key regulatory circuit, RICTOR-AKT-ZFX-UGCG-Ganglioside-EGFR-AKT, and elucidate its contribution to breast cancer progression.

18 August 2026 in Cell Reports Medicine
Verified
Journal Article
Open access
DJDolly Jain
Dolly Jain
NPNishant Pandey
Nishant Pandey
SJSomesh K. Jha
Somesh K. Jha
SSShreya Sinha
Shreya Sinha
RSRagini Singh
Ragini Singh
ABAvinash Bajaj
Avinash Bajaj
We report presence of cholinergic nerve fibers in the periphery and stroma of colon cancer tissues and their correlation with poor T cell and increased macrophage infiltration. We employed hydrogel-mediated localized delivery of an FDA-approved local anesthetic, bupivacaine (BUP), to target acetylcholine (ACh)-mediated crosstalk of cholinergic neurons with cancer and immune cells. Localized BUP-Gel therapy promotes T cell-mediated tumor inhibition and enhances the antitumor response of systemic chemotherapy and immunotherapy. Further, blockade of cancer- and immune cell-specific ACh receptors inhibits tumor growth, alters the TME, and augments the impact of chemotherapy and immunotherapy. Finally, we demonstrate that ACh receptor antagonists polarize macrophages toward an M1-like phenotype and activate T cell immunity in tumor explants of patients. Therefore, targeting cholinergic signals through localized delivery of anesthetics, as well as direct immune reprogramming via cholinergic receptor antagonists, may provide a means to modulate this tripartite crosstalk, with potential implications for therapeutic strategies.